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ACE inhibition limits chronic injury of kidney transplant even
with treatment started when lesions are established.
Background. Inhibition of the renin-angiotensin system
(RAS) prevents development of chronic allograft dysfunction
in experimental animals. Whether this therapeutic approach is
effective even if started when signs of allograft nephropathy are
already manifested has not been investigated.
Methods. To address this issue, we studied the effect of a late
treatment with the angiotensin-convertine enzyme (ACE) in-
hibitor trandolapril in the Fisher 344 to Lewis rat kidney trans-
plant model. Seven months after transplant a renal biopsy was
done for graft histology examination. Thereafter rats received
either no treatment (allograft-none) or trandolapril until sacri-
fice at month 13.
Results. All animals were alive at the end of the study with
the exception of a rat in the untreated group that died of renal
insufficiency at day 292. Despite the fact that the grafts had al-
ready signs of structural injury and function impairment at the
time treatment was stated, trandolapril completely restored re-
nal function to baseline pretransplant values. Trandolapril also
halted the progression of glomerular damage and suppressed in-
tragraft T-lymphocyte infiltration and reduced the expression of
the chemokine monocyte chemoattractant protein-1 (MCP-1).
However, trandolapril had no direct effect on T cell function,
since in vivo treatment did not modify recipient T-cell alloreac-
tivity against donor antigens.
Conclusion. These findings provide the basis for a novel treat-
ment intervention with RAS blockade that, together with phar-
macologic inhibition of the immune response, could interrupt
progression of chronic allograft dysfunction and injury.
Chronic allograft rejection is the most important cause
of renal transplant loss [1]. This is a relentlessly pro-
gressive form of graft dysfunction, spanning years to
decades and characterized morphologically by obliter-
ative vasculopathy, interstitial fibrosis with variable de-
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gree of mononuclear cell infiltration, and, in the case of
the kidney, glomerulosclerosis [2]. Although the func-
tional and morphologic findings are well characterized,
the pathophysiologic mechanisms leading to graft dete-
rioration secondary to the evolution of this process are
poorly understood.
Potential risk factors, other than immune events, in-
clude hypertension, inadequate functional nephron mass,
drug toxicity, and de novo or recurrent progressive re-
nal diseases [3, 4]. The functional and structural changes
of chronic renal allograft nephropathy show similarities
to those observed in other forms of chronic progressive
renal disease in which inadequate functioning nephron
mass has been considered the key event [5]. Indeed, trans-
plantation of a single kidney theoretically supplies half
the number of nephrons commonly available to health
subjects. This implies an increased workload per nephron
in order to maintain metabolic homeostasis [6]. Ischemic
injury at transplantation, acute rejection, and chronic cy-
closporine A (CsA) toxicity, contribute to further reduc-
ing the pool of functioning nephrons [5]. In experimental
animals, an insufficient number of nephrons due to a re-
duction in renal mass (for acquired or innate reasons)
triggers a self-perpetuating cycle of events, the hallmark
of which is excessive urinary protein excretion followed
by interstitial and glomerular inflammation and subse-
quent scarring [7]. Hemodynamic determinants of renal
injury in this setting are enhanced intraglomerular pres-
sure and flow, which are intimately involved in the devel-
opment of lesions [8]. Glomerular hypertension enhances
filtration of macromolecules across the capillary barrier,
which are then largely reabsorbed by proximal tubular
epithelial cells [7, 9]. Cell activation up-regulates genes
for inflammatory and vasoactive proteins that, in the long
run, also contribute to renal scarring [7].
Since no effective therapy exists so far for chronic
allograft dysfunction, targeting above mechanisms may
have implications for preventing progressive deteriora-
tion of renal function, which follows transplantation of
single kidney. Rationale rests on findings that blockade of
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Fig. 1. Schematic representation of the experimental design. CsA is cyclosporine A.
the renin-angiotensin system (RAS) reduced the urinary
protein excretion and protected against renal structural
injury better than conventional antihypertensive therapy
in nontransplant models of chronic renal disease, caused,
however, by lower than normal nephron numbers [10],
as well as in humans with proteinuric renal disease [4].
Studies showed already that RAS inhibition helped pre-
venting chronic graft injury in the rat models [11–14]. The
above, however, were designed as preventive interven-
tions; therefore RAS inhibitors were started very early
in the posttransplant course.
The question we wonder to address by the present
study is whether such treatment is still capable of lim-
iting disease progression or reverse lesions if started late
enough in the course of the disease when signs of re-
nal dysfunction are apparent. Answering to this might
have major clinical implication. Therefore, we have used
the Fisher 344 to Lewis rat kidney transplant model and
initiated treatment with angiotensin-converting enzyme
(ACE) inhibitor versus no treatment when rats had al-
ready proteinuria and renal function impairment. We also
sough to investigate the mechanism(s) by which pharma-
cologic inhibition of the RAS afforded protection, if any,
toward chronic allograft nephropathy.
METHODS
Animals
Inbred Fisher 344 (F344) and Lewis rats weighing 210
to 250 g were used in the experiments. Lewis rats (LEW
RT1l) acted as recipients and F344 (RT1lvl) as donors. All
animals were obtained from Charles River Italia (Calco,
Italy), housed under standard conditions, and given rat
food and water ad libitum. Procedures involving animals
and their care were conducted in conformity with the in-
stitutional guidelines that are in compliance with national
(D.L. n.116, G.U., Suppl 40, February 18, 1992; circolare
No. 8, G.U., July 14, 1994) and international laws and poli-
cies (EEC Council Directive 86/609, OJL 358, December
1987; Guide for the Care and Use of Laboratory Animals,
U.S. National Research Council, 1996).
Kidney transplantation
Kidney transplantations were performed, as previously
described [15]. Briefly, the left donor kidney was removed
and positioned orthotopically into the recipients, whose
renal vessels had been isolated and clamped, and left na-
tive kidney had been removed. End-to-end anastomosis
of renal artery, vein, and ureter were performed using 10-
O Prolene sutures (Ethicon, Inc, Somerville, NJ, USA).
Total ischemia time was <30 minutes.
Experimental design
Two experimental groups of F344 to Lewis renal al-
lograft recipients were studied (Fig. 1). An additional
group 3 underwent Lewis to Lewis syngeneic kidney
graft. All rats received CsA (5 mg/kg per day intra-
muscularly) (Novartis Farma, Milan, Italy) for the first
10 days after transplantation to prevent early acute rejec-
tion [16, 17]. After pre-transplant evaluation (baseline),
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awake systolic blood pressure, serum creatinine concen-
tration, and 24-hour urinary protein excretion were se-
rially monitored up to the end of 7 months postsurgery.
In addition, at this time point, a basal graft biopsy was
performed in all groups of animals for pretreatment his-
tologic analysis of kidney tissues. Thereafter, allografted
animals were divided in the following groups, matched
for urinary protein excretion and serum creatinine lev-
els. Group 1 (N = 6) received no treatment and group 2
(N = 6) was given the ACE inhibitor trandolapril
(0.3 mg/kg/day in the drinking water) (Abbott GmbH
& Co., KG, Ludwigshafen, Germany). The dose of tran-
dolapril was adjusted as needed to maintain systolic blood
pressure within normal range. The additional group 3 an-
imals (N = 6) were left untreated. All animals were fol-
lowed up to the end of 13 months posttransplantation.
Renal function, as serum creatinine, was monitored at
monthly intervals. At the same time points, animals were
place in individual metabolic cages for 24-hour urine col-
lections and determination of urine output and protein
excretion. Systolic blood pressure was measured serially
in conscious rats by the tail-cuff method [18]. At the end
of the study period, the animals were sacrificed and the
kidney graft removed and processed for histology and
immunohistology of graft cell infiltrate. Moreover, por-
tions of renal allograft cortex were excised, snap-frozen
in liquid nitrogen, and stored at –80◦C for later analysis
of gene expression of chemokines regulated upon activa-
tion, normal T cell expressed and secreted (RANTES)
and macrophage chemoattractant protein-1 (MCP-1)
and of transforming growth factor-b (TGF-b) by real-
time quantitative reverse transcription-polymerase chain
reaction (RT-PCR).
To examine the effect of trandolapril on T-cell allore-
activity, two additional groups of naive Lewis (RT1l) rats
were studied. Group 4 (N = 3) was untreated controls
and group 5 (N = 3) received trandolapril (0.3 mg/kg/day
in the drinking water). Both groups were in vivo primed
with intravenous infusion of allogeneic Brown-Norway
(BN) (RT1n) spleen cells (10 × 106). After 5 days, the
animals were sacrificed, lymph nodes collected, and cell
immunoreactivity was determined by mixed lymphocyte
reaction (MLR) assay against donor BN or third-party
Wistar Furth (WF) (RT1u) splenocytes. For these exper-
iments the Lewis-BN major histocompatibility complex
(MHC) disparate combination was chosen since prelimi-
nary MLR experiments showed that the alloreactivity of
either naı¨ve or primed Lewis T cells against F344 spleno-
cytes was very low.
Morphologic evaluation
Kidney specimens were fixed for 6 hours in Dubosq-
Brazil and dehydrated in alcohol. After paraffin em-
bedding, sections 3 lm in thickness (Ultrotome V)
(LKB, Bromma, Sweden) were stained with Masson’s
trichrome, hematoxylin and eosin, and by the periodic
acid-Schiff (PAS) techniques. The incidence and exten-
sion of glomerular and tubular structural lesions were es-
timated with slight modifications of previously described
methods [16]. In particular, the frequency of focal and
segmental sclerosis and hyalinosis was determined by ex-
amining all glomerular profiles contained within one or
two coronal sections from each kidney and expressed as
the percentage of the total number of glomeruli counted.
A minimum of 80 glomeruli per kidney was evaluated
for glomerulosclerosis. Tubular (atrophy, cast, and dilata-
tion) and interstitial (fibrosis and inflammation) changes
were graded on a scale of 0 to 4+: 0, no changes; 1+,
changes affecting <25% on the sample; 2+, changes af-
fecting 25% to 50% of the sample; 3+, changes affecting
50% to 75% of the sample; 4+, changes affecting 75%
to 100% of the sample. All renal biopsies were analyzed
by the same examiner, who was unaware of the nature of
the experimental group.
Immunohistology
Mouse monoclonal antibodies were used for the detec-
tion of the following rat antigens: ED-1 antigen present in
the rat monocytes and macrophages (Chemicon, Temec-
ula, CA, USA), a rat MHC class II antigen monomorphic
determinant (OX6) (Serotec, Oxford, UK), CD8 cell sur-
face glycoprotein expressed by T cytotoxic suppressor
cells (OX8) (Serotec), and CD4 cell surface glycoprotein,
a 55 kD molecule expressed by helper T cells, thymocytes,
and macrophage (W3/25) (Serotec). All antigens were
analyzed by indirect immunofluorescence technique. The
tissue fragments were frozen in liquid nitrogen, tissue sec-
tions (3 lm thick) were cut with a Mikrom 500 O cryostat
(Walldorf, Germany) and fixed in acetone. The sections
were blocked with phosphate-buffered saline (PBS)/1%
bovine serum albumin (BSA), incubated overnight at 4◦C
with the primary antibody (ED-1, 14 mg/mL; OX6, 5 lg/
mL; OX8, 1:100; W3/25, 40 lg/mL), washed with PBS,
and then incubated with Cy3-conjugated donkey anti-
mouse IgG antibodies (affinity-purified, absorbed with
rat IgG, 5 lm/mL in PBS) (Jackson Immuno-Research,
West Grove, PA, USA) for 1 hour at room temperature.
For the detection of intragraft IgG, direct immunofluores-
cence was performed using a fluorescein isothiocyanate
(FITC)-conjugated goat antirat IgG antibody (Jackson
Immunoresearch Lab, Baltimore, PA, USA) (30 lg/mL).
For each marker, the number of cells was counted in at
least 10 randomly selected high power microscope field
(×400) for each animal.
Real-time quantitative RT-PCR
To analyze gene expression of RANTES and MPC-1
and TGF-b , RNA was treated with Dnase and reverse
2256 Noris et al: ACE inhibition limits injury of kidney transplant
transcribed to cDNA. Quantitative real-time PCR was
performed on a TaqMan ABI Prism 5700 Sequence
Detection System (PE Applied Biosystems, Monza,
Italy) with SYBR Green PCR Core Reagents (Applied
Biosystems), in combination with optimal primer con-
centrations. The amplification profile consisted of 50◦C
for 2 minutes, 95◦C for 10 minutes, and 40 cycles of 95◦C
for 15 minutes, then 60◦C for 1 minute. All samples were
run in triplicate. To assess the overall cDNA content,
glyceraldheyde-3-phosphate dehydrogenase (GAPDH)
served as housekeeping gene. The following oligonu-
cleotide primers were used: rat RANTES (300 nmol/
L), 5′-CCAACCTTGCAGTCGTCTTTG-3′ and 5′-TCT
GGGTTGGCACACACTTG-3′; rat MCP-1 (300 nmol/
L), 5′-CTGTCTCAGCCAGATGCAGTTAAT-3′ and
5′-GTGAATGAGTAGCAGCAGGTGAGT-3′; rat
TGF-b (300 nmol/L), 5′-CCCTGCCCCTACATTT
GGA-3′ and 5′-GGGCAAGGACCTTGCTGTACT-3′;
and rat GAPDH (300 nmol/L), 5′-TCATCCCTGCAT
CCACTGGT-3′ and 5′-CTGGGATGACCTTGCCC
AC-3′. Similar amplification efficiencies for targets and
housekeeping genes were demonstrated by analyzing
serial cDNA dilutions, showing an absolute value of the
slope of log input cDNA amount versus  threshold
cycle (Ct) (Ct target – Ct housekeeping gene) of <0.1.
Thus, we used the Ct technique to calculate cDNA
content in each sample. Melting temperature analysis
evidenced no primer dimers or aspecific amplification
products. Controls consisting of ddH2O or RT-RNA
were negative for targets and housekeeping.
Mixed lymphocyte reaction
Lymph node cells were isolated from responder Lewis
rats by sieving and were cultured (1 × 106/well) with irra-
diated (4000 rad) splenocytes (1 × 106/well) from donor
BN, third-party WF, or Lewis rats (control combination)
for 5 days. Cells were then pulsed for 18 hours with 1 lCi
[3H]-thymidine and uptake of radioactivity was measured
by liquid scintillation counting. The stimulation index (SI)
was calculated as follows [19]:
SI = cpm in allogeneic MLR
cpm in control combination
Statistical analysis
Results are given as a mean ± SE. For functional pa-
rameters, the significance of differences between individ-
ual groups, after two-way analysis of variance (ANOVA),
was established by using the Tukey-Cicchetti test for
multiple comparisons. Estimates of renal injury from
morphologic studies and immunohistochemical results
were analyzed by the nonparametric Kruskal-Wallis test
for multiple comparisons. Differences in real-time re-
nal expression data between untreated and trandolapril-
Table 1. Body weight and systolic blood pressure in the three groups
of transplanted rats
Basal Month 7 Month 9 Month 13
Body weight g
Untreated 224 ± 8a 463 ± 13 489 ± 9 516 ± 25
Trandolapril 232 ± 5a 449 ± 15 485 ± 15 515 ± 16
Syngeneic 266 ± 13 456 ± 15 493 ± 12 520 ± 16
Systolic blood pressure mm Hg
Untreated 118 ± 3 136 ± 4a,b 145 ± 3b 120 ± 6c
Trandolapril 118 ± 3 138 ± 3b 110 ± 7 105 ± 6a
Syngeneic 124 ± 3 121 ± 2 120 ± 4 130 ± 3
Data are mean ± SE.
a P < 0.05 vs. syngeneic; bP < 0.05 vs. basal; cP < 0.05 vs. trandolapril.
treated allograft recipients were analyzed by Student t
test for unpaired data (two-tailed). Statistical significance
was defined as P < 0.05.
RESULTS
All rats grew at similar rates without significant differ-
ences in body weights between untreated, trandolapril,
and syngeneic groups (Table 1).
Five out of six untreated recipients (group 1) survived
up to the month 13 follow-up (mean survival 373 ±
16 days). In the trandolapril group (group 2), all six an-
imals were alive at the end of the study period (mean
survival 390 days). All six rats who underwent syngeneic
kidney graft (group 3) survived up to the end of the
follow-up.
As shown in Table 1, at 7 months after transplant (be-
fore starting any treatment) allografted rats from groups
1 and 2 were slightly hypertensive (P < 0.05 vs. baseline).
In untreated rats, systolic blood pressure remained ele-
vated until month 9 posttransplant, but thereafter sponta-
neously declined toward normal baseline values. In group
2 rats, who started trandolapril treatment at month 7
postsurgery, systolic blood pressure declined soon after
beginning antihypertensive therapy, and remained well
controlled throughout the follow-up (Table 1). In rats
with syngeneic kidney grafts, systolic blood pressure did
not change significantly during the entire study period.
Graft function
Figure 2 shows the time course of serum creatinine con-
centration as an index of renal function in animals from
individual groups that were alive at given time points af-
ter transplant. At month 7 postsurgery, animals with kid-
ney allografts had serum creatinine concentrations sig-
nificantly higher (P < 0.05) than baseline pretransplant
values or rats of group 3 with syngeneic grafts. In un-
treated animals of group 1, a further progressive increase
in serum creatinine was found during the following the
study period. Trandolapril reduced serum creatinine lev-
els to the extent that, after 2 months of treatment, normal
values (0.54 ± 0.03 mg/dL), comparable to pretransplant
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Fig. 2. Time course of serum creatinine in the three groups of trans-
planted rats. Untreated is untreated allograft recipients. Values are the
mean ± SE. ◦P < 0.05 vs. basal and syngeneic; #P < 0.01 vs. trandolapril
and syngeneic; ∗P < 0.01 vs. 7 months.
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Fig. 3. 24-hour urinary protein excretion of the different experimental
groups as a function of time after transplant. Untreated is untreated
allograft recipients. Values are mean ± SE. ◦P < 0.05 vs. basal; #P <
0.05 vs. trandolapril and syngeneic; ∗P < 0.01, +P < 0.05 vs. 7 months;
§P < 0.05 vs. syngeneic.
basal values (0.52 ± 0.01 mg/dL), were achieved. At this
time point, serum creatinine in this group was similar to
that of syngeneic transplanted rats (0.54 ± 0.04 mg/dL).
At the end of the study, trandolapril-treated rats showed
normal graft function, with serum creatinine values sig-
nificantly (P < 0.01) lower than untreated group 1.
As depicted in Figure 3, urinary proteins excretion was
significantly higher (P < 0.05 vs. baseline) at month 7
posttransplant in both groups 1 and 2 who had kidney
allografts than at pretransplant baseline. At the same
time, protein excretion in syngenic graft recipients was
numerically lower than in the allograft groups. Progres-
sive increase in urinary proteins was observed over the
following 6 months in untreated rats. Chronic inhibition
of the RAS with trandolapril in group 2 initially not only
prevented, but also reversed progressive urinary protein
excretion during the next 4 months, reaching values com-
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Fig. 4. Glomerular injury in the three groups of transplanted rats at
7 months (before start of treatment) and at the end of the 13-month
follow-up period. Untreated is untreated allograft recipients. Values
are mean ± SE. ◦P < 0.05 vs. 7 months; #P < 0.01 vs. trandolapril and
syngeneic; ∗P < 0.05 vs. syngeneic.
Table 2. Tubulointerstitial injury in the three groups of transplanted
rats
Untreated Trandolapril Syngeneic
Tubulointerstitial injury (score)
Month 7 0.41 ± 0.2a 0.58 ± 0.3a 0.20 ± 0
Month 13 1.90 ± 0.4a,b 1.60 ± 0.5 0.87 ± 0.1b
Data are mean ± SE
aP < 0.05 vs. syngeneic; bP < 0.05 vs. 7 months
parable to those of syngeneic grafted rats (P < 0.05 vs.
group 1 at month 11). Thereafter, however, proteinuria
started again to increase, so that at the end of the study
period mean value was significantly higher than at pre-
treatment month 7 (P < 0.05). Nevertheless, in this group,
the urinary protein excretion was numerically lower than
in untreated rats of group 1, but higher than in syngeneic
graft rats. An age-related slowly progressive increase in
protein excretion rate was found in animals with kidney
syngeneic transplant.
Graft morphology
Histology findings from graft biopsies performed at
months 7 and 13 posttransplant are reported in Figure 4
and Table 2. Morphologic evaluation on month 7 pre-
treatment biopsies showed focal and segmental glomeru-
losclerosis affecting 5.7% ± 2.6% and 16.5% ± 4.9% of
glomeruli of group 1 and 2 allografts (P < 0.05 vs. syn-
geneic grafts at 7 months), whereas glomerular injury was
negligible in syngeneic grafts (Fig. 4). At month 13, sec-
tions of allografts from untreated rats showed further in-
crease in glomerular injury involving 54.0% ± 11.5% of
glomeruli (P < 0.05 vs. 7 months). Trandolapril halted the
progression of graft glomerular lesions, so that 25.4% ±
10.2% of glomeruli were affected, a value only numer-
ically higher than in the same group 2 at pretreatment
month 7, but significantly (P < 0.01) lower than that
in untreated rats of group 1 (Fig. 4). In keeping with
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Fig. 5. Intragraft immunostaining of ED-1+ macrophages, OX6+
[major histocompatibility complex class II (MHC II+)] cells, CD8+,
and CD4+ lymphocytes in the three groups of transplanted rats at the
end of the 13-month follow-up. Untreated is untreated allograft recipi-
ents. Values are mean ± SE. ◦P < 0.05 vs. control.
changes of proteinuria, glomerular injury increased with
time in syngeneic grafts reaching at 13 months statistical
significance (P < 0.05) as compared to 7 months. Tubu-
lointerstitial injury in untreated rats of group 1, already
present at month 7 postsurgery, was markedly and sig-
nificantly higher at the end of the study period (Table 2)
(P < 0.05 vs. 7 months). Trandolapril partially limited the
increase of tubulointerstitial injury, whose mean score
value at month 13 posttransplant was numerically lower
than in untreated rats, but higher than in syngeneic grafts
(Table 2).
Immunohistology
A detailed immunohistology evaluation of allografted
and syngeneic animals studied at the end of the 13-
month follow-up was undertaken (Fig. 5). In kidney from
trandolapril-treated rats, interstitial infiltration of CD4+
and CD8+ T cells was significantly (P < 0.05) lower than
in untreated rats of group 1. Similar results were found
with ED-1+ monocyte/macrophages (P < 0.05 vs. un-
treated) and MHC class II cells (OX6+) that were nu-
merically lower in trandolapril-treated than in untreated
animals. No significant difference in the interstitial ac-
cumulation of infiltrating cells between trandolapril and
syngeneic groups was found for each of the cell types
considered. Moreover, in trandolapril-treated rats, mean
score of IgG deposition at the end of the study period was
numerically but not significantly lower than in untreated
rats of group 1 (glomeruli, trandolapril 0.58 ± 0.66 and
untreated 1.50 ± 1.00; cortical tubuli, trandolapril 1.58 ±
1.43 and untreated, 2.40 ± 0.89; and medullary tubuli,
trandolapril 1.00 ± 1.55 and untreated, 1.20 ± 1.30).
Intragraft expression studies
Real time RT-PCR studies on allograft tissue at the
end of the 13-month follow-up revealed a beneficial ef-
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Fig. 6. Effect of in vivo administration of trandolapril on T-cell allore-
active response. Lewis rats received a pulse of allogenic Brown-Norway
(BN) splenocytes (10 × 106 intravenously.) and were either left un-
treated (BN spleen) or were treated with trandolapril (BN spleen +
trandolapril). Five days later, animals were sacrificed and lymph node
cells were isolated. The lymphocyte proliferative response (stimulation
index) against donor BN or third-party Wistar Furth (WF) stimulators
was assessed in mixed lymphocyte reaction (MLR) in vitro. Spleen is
splenocytes.
fect of trandolapril on intragraft MCP-1 expression that
was significantly lower than in untreated rats of group 1
(trandolapril, MCP-1/GAPDH, 0.0073 ± 0.0035 vs. un-
treated 0.023 ± 0.07, P < 0.05). At variance, no sig-
nificant difference in RANTES and TGF-b expression
was found in trandolapril-treated and in untreated rats
(RANTES/GAPDH, 0.030 ± 0.024 vs. 0.032 ± 0.033;
TGF-b/GAPDH, 0.033 ± 0.005 vs. 0.032 ± 0.012).
T-cell alloreactivity by MLR
In additional nontransplanted Lewis rats, the effect of
short-course trandolapril on T-cell immune response was
also evaluated (Fig. 6). Lymphocytes from naive Lewis
rats normally proliferated in vitro when stimulated with
either BN or WF splenocytes. T cells from Lewis rats
previously pulsed with BN allogeneic splenocytes further
proliferated when cultured in vitro with donor BN but not
third-party WF stimulator splenocytes. In vivo treatment
with trandolapril had no effect on Lewis T cell alloreac-
tivity against donor BN or third-party WF alloantigens.
DISCUSSION
Results of the present study show that a late treat-
ment with the ACE inhibitor trandolapril fully restored
normal graft function, limited progressive proteinuria,
and stabilized glomerulosclerosis changes in a rat kid-
ney transplant model with chronic renal dysfunction and
overt proteinuria. These data indicate that, once initi-
ated, chronic rejection is not necessarily an inevitable
process but can be interrupted by the RAS blockade.
This is the first experimental attempt of inhibiting RAS
as therapeutic strategy to enhance graft longevity and
preserve adequate renal allograft function in a setting
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of graft dysfunction and overt chronic proteinuria. The
experiments were performed in the Fisher to Lewis rat
model of renal transplantation that is considered to be a
useful model of chronic allograft nephropathy [20]. The
progressive changes occurring mirror most, although not
all, the changes experienced by patients with chronic allo-
graft nephropathy who themselves manifest proteinuria
of varying degree, in conjunction with progressive dif-
fuse glomerulosclerosis, interstitial lesions, and vascular
obliteration [21].
Few reports are available on the effects of late inhi-
bition of the RAS on renal function and structure in
nontransplanted experimental rat models of renal dis-
ease progression [22–27]. ACE inhibitors given late dur-
ing the animal’s life, when animals were already heavily
proteinuric, decreased blood pressure and proteinuria,
and stopped the disease from progressing in Munich Wis-
tar Fromter (MWF) rats [26], genetically programmed to
develop proteinuria and progressive renal damage with
age. Moreover, sclerosis was remodeled in aging rats by
inhibiting the RAS with an angiotensin II (Ang II) recep-
tor antagonist given at high doses for 6 months [27]. More
recently, combination of an ACE inhibitor and an Ang II
receptor antagonist, in order to maximize the Ang II
blockade, improved glomerular ultrafiltration coefficient
(Kf), fully eradicated proteinuria, and partially regressed
the early glomerulosclerotic lesions and tubulointerstitial
injury in MWF rats [28]. Thus, while progressive deteri-
oration of renal function was previously considered an
inexorable process, occasional observations in humans
and subsequent, more systematic studies in both humans
and experimental animals have indicated collectively that
improvement of renal function, remission of proteinuria,
and even regression of renal structural injury may ac-
tually occur [29]. Here, we have documented that there
may also be a window of opportunity for chronic allo-
graft nephropathy where specific interventions, such as
RAS blockade, may halt or even regress the pace of dis-
ease progression. In the present study, graft dysfunction
was rapidly normalized by trandolapril, and serum cre-
atinine concentration remained thereafter stable within
the normal range. Together, normalized graft function,
remarkably reduced urinary protein excretion, stable
glomerular structural lesions, and limited tubulointersti-
tial changes, indicate that late ACE inhibition allowed
the interruption of the progression of chronic allograft
nephropathy.
After the initial marked reduction in urinary protein
excretion, while still on chronic ACE inhibitor treatment,
proteinuria started again to slowly increase. An explana-
tion could be that the dose of ACE inhibitor used was not
high enough to completely block the RAS eventually re-
sulting in the slow escape from the ACE inhibition and its
antiproteinuric effect. An alternative pathway to graft in-
jury should be also taken into consideration in the relapse
of proteinuria we found in trandolapril-treated rats. Re-
cent evidence emphasized contributions of alloantigen-
dependent factors in the pathogenesis of chronic renal
allograft failure [4], which add to the potential deleteri-
ous effect of Ang II. The above involve intragraft T-cell
and macrophage activation [30–32]. In particular, it has
been suggested that continuous T-cell recognition of al-
loantigens, presumably via the indirect pathway, and full
cell activation through costimulatory signals are events
that may play an important role in the progression of
chronic rejection [31]. Target interventions of blocking
T-cell costimulatory activation could be of value. This
possibility is supported by previous findings in the same
experimental rat model of chronic kidney allograft re-
jection that late blockade of T-cell costimulation with
the fusion protein CTLA4Ig transiently reduced urinary
protein excretion [31]. Since in our animals trandolapril
was the only single chronic treatment used, the ongoing
immune response may have been left unabated, account-
ing for the alloantigen-dependent and cell-mediated con-
tribution to proteinuria. Finding that trandolapril, given
in vivo to nontransplanted rats pulsed with allogeneic
splenocytes, did not affect ex vivo T-cell alloreactivity
against donor or third-party alloantigens in the MLR
assay seems to rule out the possibility that Ang II in-
hibition in this model could exert immunomodulatory
properties [33].
Among the factors associated with tissue injury in pro-
gressive renal disease, other than glomerular hyperten-
sion and proteinuria, are infiltrating mononuclear cells,
macrophages and T cells, which become activated and
participate in parenchyma scarring by synthesizing and
secreting fibrogenic cytokines, which stimulate interstitial
fibroblast proliferation and matrix accumulation [7, 34,
35]. The key role of infiltrating cells in inducing intersti-
tial injury leading to further inflammation and fibrosis has
been documented extensively in the last few years [7, 36].
Furthermore, therapeutic interventions that dampen the
interstitial inflammatory response preserve renal func-
tion from progressive deterioration [7]. In this context,
the interstitial inflammatory reaction in biopsy specimens
from trandolapril-treated rats at the end of the 13-month
follow-up was markedly lower than in untreated allo-
grafts. It is tempting to speculate that limiting protein
excretion rate and tissue inflammatory response by phar-
macologic inhibition of Ang II synthesis may have syn-
ergistically contributed to preserve graft function within
the normal range. Interestingly, recent evidence also sug-
gests that Ang II may promote the synthesis of a va-
riety of cell-adhesion molecules and cytokines possibly
via reactive oxygen intermediates and activation of the
transcription factor nuclear factor-kB (NF-kB) [37–39].
Molecules with NF-kB-responsive elements include in-
tercellular adhesion molecule-1 (ICAM-1) and MCP-1.
Coordinated expression of these latter factors might be
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expected to promote local macrophage and lymphocyte
recruitment in the allograft. Our data show that inhibition
of RAS also attenuated the intragraft cortical expression
of the potent macrophage and lymphocyte chemokine,
MCP-1, which may ultimately have been related to the
beneficial effect of the treatment on the interstitial in-
flammatory cell infiltration. These findings may be consid-
ered consistent with suppression of leukocyte-associated
cytokine and leukocyte-chemoattractant expression by
Ang II receptor blockade in Fisher to Lewis rat kid-
ney allografts, when treatment was started very early
postsurgery [14].
CONCLUSION
Our data indicate that inhibition of Ang II synthesis
induces a complete normalization of graft function and
some degree of remission of proteinuria, and stabilized
kidney structural changes even if started late in the course
of the disease, when lesions are already established.
These effects are associated with reduction in allograft
cell infiltration and attenuated expression of molecules
involved in macrophage and lymphocyte recruitment.
Translating these considerations into clinical transplan-
tation, these findings provide the basis for a novel treat-
ment intervention with RAS blockade that, together with
pharmacologic inhibition of the immune response, could
interrupt progression of chronic allograft dysfunction and
injury. This eventually would result in prolongation of
graft survival and reduction of the rate of kidney allograft
loss.
ACKNOWLEDGMENTS
This work has been partially supported by grants from Associazione
Ricerca Trapianti and from Fondazione Monzino. Dr. Paola Cassis is
a recipient of a fellowship from Associazione Ricerca Malattie Rare,
through the generosity of Banco di Brescia.
Reprint requests to Marina Noris, Chem.Pharm.D., Mario Negri Insti-
tute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo,
Italy.
E-mail: noris@marionegri.it
REFERENCES
1. PAUL L: Chronic renal transplant loss. Kidney Int 47:1491–1499,
1995
2. TILNEY NL, WHITLEY WD, DIAMOND JR, et al: Chronic rejection: An
undefined conundrum. Transplantation 52:389, 1991
3. PAUL LC, BENEDIKTSSON H: Chronic transplant rejection: Magnitude
of the problem and pathogenic mechanisms. Transplant Rev 134:5–
19, 1993
4. REMUZZI G, PERICO N: Protecting single-kidney allografts from long-
term functional deterioration. J Am Soc Nephrol 9:1321–1332, 1998
5. MACKENZIE HS, BRENNER BM: Antigen-independent determinants
of late renal allograft outcome: the role of renal mass. Curr Opin
Nephrol Hyperten 5:289–296, 1996
6. BRENNER BM, COHEN RA, MILFORD EL: In renal transplantation,
one size may not fit all. J Am Soc Nephrol 3:162–169, 1992
7. REMUZZI G, BERTANI T: Pathophysiology of progressive
nephropathies. N Engl J Med 339:1448–1456, 1998
8. BRENNER BM: Hemodynamically mediated glomerular injury and
the progressive nature of glomerular disease. Kidney Int 23:647–655,
1983
9. REMUZZI G: Abnormal protein traffic through the glomerular bar-
rier induces proximal tubular cell dysfunction and causes renal in-
jury. Curr Opin Nephro Hyperten 4:339–342, 1995
10. TAAL MW, BRENNER BM: Renoprotective benefits of RAS inhibi-
tion: from ACEI to angiotensin II antagonists. Kidney Int 57:1803–
1817, 2000
11. MACKENZIE HS, ZIAI F, NAGANO H, et al: Candesartan cilexetil re-
duces chronic renal allograft injury in Fisher → Lewis rats. J Hy-
pertens 15(Suppl 6):S21–S25, 1997
12. BENEDIKTSSON H, CHEA R, DAVIDOFF A, PAUL LC: Antihypertensive
drug treatment in chronic renal allograft rejection in the rat. Effect
on structure and function. Transplantation 62:1634–1642, 1996
13. AMUCHASTEGUI SC, AZZOLLINI N, MISTER M, et al: Chronic allo-
graft nephropathy in the rat is improved by angiotensin II receptor
blockade but not by calcium channel antagonism. J Am Soc Nephrol
9:1948–1955, 1998
14. ZIAI F, NAGANO H, KUSAKA M, et al: Renal allograft protection with
losartan in Fisher → Lewis rats: Hemodynamics, macrophages, and
cytokines. Kidney Int 57:2618–2625, 2000
15. NORIS M, AZZOLLINI N, MISTER M, et al: Peripheral donor leukocytes
prolong survival of rat renal allografts. Kidney Int 56:1101–1112,
1999
16. NORIS M, AZZOLLINI N, PEZZOTTA A, et al: Combined treatment with
mycophenolate mofetil and an angiotensin II receptor antagonist
fully protects from chronic rejection in a rat model of renal allograft.
J Am Soc Nephrol 12:1937–1946, 2001
17. DIAMOND JR, TILNEY NL, FRYE J, et al: Progressive albuminuria and
glomerulosclerosis in a rat model of chronic renal allograft rejection.
Transplantation 54:710–716, 1992
18. PFEFFER JM, PFEFFER MA, FROHLICH ED: Validity of an indirect
tail-cuff method for determining systolic arterial pressure in unanes-
thetized normotensive and spontaneously hypertensive rats. J Lab
Clin Med 78:957–962, 1971
19. NORIS M, CUGINI D, CASIRAGHI F, et al: Thymic microchimerism cor-
relates with the outcome of tolerance-inducing protocols for solid
organ transplantation. J Am Soc Nephrol 12:2815–2826, 2001
20. MACKENZIE HS, TULLIUS SG, HEEMANN UW, et al: Nephron supply
is a major determinant of long-term renal allograft outcome in rats.
J Clin Invest 94:2148–2152, 1994
21. DIAMOND JR, TILNEY NL, FRYE J, et al: Progressive albuminuria and
glomerulosclerosis in a rat model of chronic renal allograft rejection.
Transplantation 54:710–716, 1992
22. MEYER TW, ANDERSON SA, RENNKE HG, BRENNER BM: Reversing
glomerular hypertension stabilizes established glomerular injury.
Kidney Int 31:752–759, 1987
23. BEUKERS JJB, VAN DER WAL A, HOEDEMAEKER PJ, WEENING JJ: Con-
verting enzyme inhibition and progressive glomerulosclerosis in the
rat. Kidney Int 32:794–800, 1987
24. INSERRA F, ROMANO LA, DE CAVANAGH EM, et al: Renal interstitial
sclerosis in aging: Effects of enalapril and nifedipine. J Am Soc
Nephrol 7:676–680, 1996
25. RUIZ-TORRES MP, BOSCH RJ, O’VALLE F, et al: Age-related increase
in expression of TGF-b1 in the rat kidney: Relationship to morpho-
logic changes. J Am Soc Nephrol 9:782–791, 1998
26. REMUZZI A, FASSI A, BERTANI T, et al: ACE inhibition induces re-
gression of proteinuria and halts progression of renal damage in a
genetic model of progressive nephropathy. Am J Kidney Dis 34:626–
632, 1999
27. MA LJ, NAKAMURA S, WHITSITT JS, et al: Regression of sclerosis
in aging by an angiotensin inhibition-induced decrease in PAI-1.
Kidney Int 58:2425–2436, 2000
28. REMUZZI A, GAGLIARDINI E, DONADONI C, et al: Effect of angiotensin
II antagonism on the regression of kidney disease in the rat. Kidney
Int 62:885–894, 2002
29. RUGGENENTI P, SCHIEPPATI A, REMUZZI G: Progression, remis-
sion, regression of chronic renal diseases. Lancet 357:1601–1608,
2001
30. RUSSELL ME, HANCOCK WW, AKALIN E, et al: Chronic cardiac re-
jection in the Lewis to F344 rat model: Blockade of CD28-B7
costimulation by CTLA4Ig modulates T cell and macrophage
Noris et al: ACE inhibition limits injury of kidney transplant 2261
activation and attenuates arteriosclerosis. J Clin Invest 97:833–838,
1996
31. CHANDRAKER A, AZUMA H, NADEAU K, et al: Late blockade of T
cell costimulation interrupts progression of experimental chronic
allograft rejection. J Clin Invest 101:2309–2318, 1998
32. SOO KIM K, DENTON MD, CHANDRAKER A, et al: CD28-B7-mediated
T cell costimulation in chronic cardiac allograft rejection. Differen-
tial role of B7-1 in initiation versus progression of graft arterioscle-
rosis. Am J Pathol 158:977–986, 2001
33. NATARAJ C, OLIVERIO MI, MANNON RB, et al: Angiotensin II reg-
ulates cellular immune response through a calcineurin-dependent
pathway. J Clin Invest 104:1693–1701, 1999
34. ABBATE M, ZOJA C, CORNA D, et al: In progressive nephropathies,
overload of tubular cells with filtered proteins translates glomerular
permeability dysfunction into cellular signals of interstitial inflam-
mation. J Am Soc Nephrol 9:1213–1224, 1998
35. RUIZ-ORTEGA M, LORENZO O, SUZUKI Y, et al: Proinflammatory
actions of angiotensins. Curr Opin Nephrol Hyperten 10:321–329,
2001
36. EDDY AA: Molecular insights into renal interstitial fibrosis. J Am
Soc Nephrol 7:2495–2508, 1996
37. SCHRECK R, MEIER B, MANNEL D, et al: Dithiocarbamates as potent
inhibitor of nuclear factor kappa B activation in intact cells. J Exp
Med 175:1181–1194, 1992
38. GRIENDLING KK, USHIO FM, LASSEGUE B, ALEXANDER RW: An-
giotensin II signaling in vascular smooth muscle:new concepts. Hy-
pertension 29:366–373, 1997
39. RUIZ-ORTEGA M, BUSTOS C, HERNANDEZ PM, et al: Angiotensin II
participates in mononuclear cell recruitment in experimental im-
mune complex nephritis through nuclear factor-kappa B activa-
tion and monocyte chemoattractant protein-1 synthesis. J Immunol
161:430–439, 1998
